Janssen Pharmaceutica NV and Johnson & Johnson (China) Investment Ltd. have identified substituted phenyl-1H-pyrrolo [2, 3-c] pyridine derivatives acting as menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.
Janssen R&D (Ireland) and Johnson & Johnson (China) Investment Ltd. have disclosed fused heterocyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) infections.
Impact Therapeutics (Shanghai) Inc. has synthesized nitrogen-containing fused heteroaromatic bicyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Researchers from Nanjing University and China Pharmaceutical University have reported the discovery and preclinical evaluation of a novel KRAS(G12C) inhibitor.
The primary reason for hospitalization of patients with sickle cell disease (SCD) is an acute systemic painful vaso-occlusive episode (VOE), which serves as an antecedent to acute chest syndrome (ACS). It has been previously demonstrated that P-selectin-dependent neutrophil-platelet aggregation and the complement pathway activation contribute to the vaso-occlusive pathophysiology in SCD.
Transcode Therapeutics Inc. has received clearance from the FDA to proceed with a first-in-human phase 0 trial of TTX-MC138 in cancer patients with advanced solid tumors. A single dose of radiolabeled TTX-MC138 will be followed by noninvasive PET-MRI to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions.
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in persons over the age of 50. While poorly understood, AMD pathogenesis begins with structural disorganization of the outer-blood-retina-barrier (oBRB), containing retinal pigment epithelium (RPE) and associated Bruch’s membrane.
Simcere Pharmaceutical Group Ltd. has received IND approval from China's National Medical Products Administration (NMPA) for two immuno-oncology bispecific antibodies, SIM-0348 and SIM-0237.
Ice, juice, the exact measure of liquor, a few drops of Angostura... What goes into a good New Year’s Eve cocktail? According to researchers working on vaccines for the most elusive viruses, it will be time soon to toast next-generation vaccines. If 2020 was the year of the COVID-19 pandemic, and in 2021 the year of mRNA vaccinations, 2022 brought polyvalent designs of antigens, evaluated highly neutralizing antibodies, and fine-tuned mRNA technology against SARS-CoV-2, HIV and the flu.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. researchers have developed prodrugs acting as apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer, particularly chronic myeloid leukemia.
RSS
